Rituximab + Immunotherapy for Follicular Lymphoma
Trial Summary
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on anticancer therapies or investigational agents close to the start of the study. It's best to discuss your specific medications with the study team.
What data supports the effectiveness of the drug combination Rituximab and Avelumab for treating follicular lymphoma?
Rituximab has been shown to significantly improve outcomes for patients with follicular lymphoma, especially when used in combination with other treatments. It has been effective in achieving long-term remission and prolonging survival, and it works well with both chemotherapy and other targeted therapies.12345
What safety data exists for Rituximab and Utomilumab in treating follicular lymphoma?
How is the drug combination of Rituximab, Avelumab, PF04518600, and Utomilumab unique for treating follicular lymphoma?
This drug combination is unique because it combines Rituximab, a well-established monoclonal antibody targeting CD20 on B-cells, with Avelumab and Utomilumab, which are immunotherapies that enhance the body's immune response against cancer cells. This approach aims to improve treatment outcomes by leveraging both direct targeting of cancer cells and boosting the immune system, which is different from traditional chemotherapy-based treatments.12111213
What is the purpose of this trial?
This trial is testing a combination of three drugs to treat follicular lymphoma. It aims to find out if this mix is safe and effective. Rituximab targets cancer cells, while Utomilumab and Avelumab help the immune system fight the cancer. Epratuzumab is another drug being tested for its effectiveness in treating follicular lymphoma.
Research Team
Caron A. Jacobson, MD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for adults over 18 with follicular lymphoma that's relapsed after treatment or hasn't been treated yet, except those with severe allergies to monoclonal antibodies, autoimmune diseases, active infections, other cancers within the last three years (some exceptions apply), and certain heart conditions. Participants need functioning major organs and can't be pregnant or breastfeeding.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Rituximab, Utomilumab, Avelumab, and/or PF-04518600 in various combinations. Rituximab is administered for four weekly treatments in cycle 1, while other drugs are administered at specified intervals.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with assessments for progression-free survival and overall survival.
Long-term follow-up
Participants are monitored for overall survival with less frequent contact.
Treatment Details
Interventions
- Avelumab
- PF04518600
- Rituximab
- Utomilumab
Avelumab is already approved in European Union, United States, Japan for the following indications:
- Merkel cell carcinoma
- Renal cell carcinoma
- Urothelial carcinoma
- Merkel cell carcinoma
- Renal cell carcinoma
- Urothelial carcinoma
- Merkel cell carcinoma
- Renal cell carcinoma
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University